Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series

Erica Lin¹, Andrew H. Limper² and Teng Moua²*

Abstract

Background: Rheumatoid arthritis (RA) is a systemic autoimmune condition characterized by erosive inflammation of the joints. One rare pulmonary manifestation is obliterative bronchiolitis (OB), a small airways disease characterized by the destruction of bronchiolar epithelium and airflow obstruction.

Methods: We retrospectively reviewed the clinical data of patients with rheumatoid arthritis-associated obliterative bronchiolitis (RA-OB) from 01/01/2000 to 12/31/2015. Presenting clinical features, longitudinal pulmonary function testing, radiologic findings, and independent predictors of all-cause mortality were assessed.

Results: Forty one patients fulfilled criteria for diagnosis of RA-OB. There was notable female predominance (92.7%) with a mean age of 57 ± 15 years. Dyspnea was the most common presenting clinical symptom. Median FEV1 was 40% (IQR 31–52.5) at presentation, with a mean decline of −1.5% over a follow-up period of thirty-three months. Associated radiologic findings included mosaic attenuation and pulmonary nodules. A majority of patients (78%) received directed therapy including long-acting inhalers, systemic corticosteroids or other immunosuppressive agents, and macrolide antibiotics. All-cause mortality was 27% over a median follow-up of sixty-two months (IQR 32–113). No distinguishable predictors of survival at presentation were found.

Conclusions: RA-OB appears to have a stable clinical course in the majority of patients despite persistent symptoms and severe obstruction based on presenting FEV1.

Keywords: Rheumatoid arthritis, Obliterative bronchiolitis, Small airways disease

Background

Rheumatoid arthritis (RA) is a systemic autoimmune condition characterized primarily by erosive inflammation of the joints affecting approximately 1% of the world’s population [1]. It is often associated with high morbidity due to extra-articular manifestations. Pulmonary manifestations of rheumatoid arthritis include airways disease, interstitial lung disease, parenchymal nodules, pleural disease, and pulmonary vasculitis [1–3]. These pulmonary findings can present early in the disease course [4] and account for up to 10% of rheumatoid arthritis-associated deaths [5, 6].

Obliterative bronchiolitis (OB, synonymous with constrictive bronchiolitis) is a rare small airways disease characterized by the destruction of bronchiolar epithelium and subsequent progressive airflow obstruction [7]. It has been found in a wide range of clinical settings. While obliterative bronchiolitis after transplantation has been well-described [8, 9], its presentation in non-transplant patients is still poorly understood and continues to be a source of interest [10]. Outside of organ transplantation, obliterative bronchiolitis is most commonly associated with connective tissue diseases, such as rheumatoid arthritis [8, 9]. Unfortunately, due to its rarity, there is still a paucity of literature regarding the clinical course of rheumatoid arthritis-associated obliterative bronchiolitis (RA-OB). It has been previously described as variable, in that some patients have periods of prolonged stability while others have a more rapid decline with respiratory failure and death [7].
Therefore, its longitudinal progression should be further evaluated for appropriate management and counseling of patients.

The majority of published studies represent individual case reports or case series, often characterizing the suspected association with penicillamine therapy used for management of RA [11–17]. One concern in assessing the functional history of such patients is the contribution of FEV1 decline from smoking. In a large case series that described both rheumatoid arthritis-associated follicular and obliterative bronchiolitis in fifteen biopsy-proven cases, a third had history of tobacco use [18]. The largest published retrospective study on RA-OB to date included over half with radiologic evidence of emphysema, perhaps confounding the severity of pulmonary function testing, perhaps confounding the severity of pulmonary function testing [19]. The purpose of this study was to characterize the clinical course and overall prognosis of patients with suspected RA-OB in the absence of radiologic emphysema.

Methods

Study population

Institutional Review Board approval was obtained (IRB #16–009418). The electronic medical record was searched to identify patients with RA-OB using key terms “rheumatoid arthritis” and “bronchiolitis.” Consecutive patients with suspected RA-OB evaluated at our institution from 1/1/2000 to 12/31/2015 were reviewed. Rheumatoid arthritis was defined according to criteria established by the American College of Rheumatology [20], confirmed with formal Rheumatology consultation. Obliterative bronchiolitis was defined using the following criteria: 1) presence of active compatible respiratory symptoms including dyspnea or cough plus 2) abnormal pattern on pulmonary function testing (PFT) in the absence of radiologic emphysema or 3) evidence of small airways disease on high-resolution computed tomography (CT) of the chest such as mosaicism or air trapping or centrilobular nodules or 4) histopathologic features on lung biopsy consistent with OB, when available in 5) the absence of an alternative diagnosis that could account for the findings. Indeed, there is not a standardized definition of RA-OB. The above-mentioned definition is based off findings by Hertz et al. [8]. Final diagnoses were made by multidisciplinary review at the time of biopsy. In order to select patients with obstructive airways disease attributed to suspected OB alone, patients were excluded if there was concomitant emphysema on imaging. Presenting clinical features, longitudinal PFTs, radiologic findings, therapeutic interventions, and all-cause mortality were collected from the electronic medical record. PFTs were performed in our laboratory using Medical Graphics equipment through standardized protocols by an experienced technician [21]. Collated PFT findings included percent predicted total lung capacity (TLC%), forced vital capacity (FVC%), forced expiratory volume in the first second (FEV1%), and diffusing capacity for carbon monoxide (DLCO%). Airflow obstruction was defined as FEV1 to FVC ratio less than the lower limit of normal (LLN), with staging of obstructive disease based on GOLD criteria for FEV1 [22]. Bronchodilator response was defined as spirometric findings of FEV1 improvement greater than 12% and g200 mL from baseline spirometry. High-resolution CT images were obtained using a scanning protocol in which 10–20 mm images were reconstructed using a high-spatial-resolution algorithm. Along with air-trapping or mosaicism, radiologist assessed presence of other rheumatoid-related pulmonary processes such as suspected rheumatoid lung nodules, lung fibrosis or fibrotic disease, pleural effusion, and non- traction related bronchiectasis, were collated. Biopsies were obtained by either surgical or transbronchial approach and reviewed by an experienced thoracic pathologist at the time of biopsy.

Statistical analysis

Statistical analysis was performed using JMP Software (Version 10.0, SAS Corporation 2012). Quantitative variables were expressed as mean ± standard deviation or median and interquartile range, and qualitative variables as counts and percentage. Comparison of PFT at diagnosis and last available follow-up was assessed using Wilcoxon signed-rank test. Independent predictors of all-cause mortality were assessed using univariable Cox proportional hazards regression. Analysis was performed with statistical significance defined as two-tailed p values < 0.05.

Results

Eighty-nine patients were found using the aforementioned key search terms. Upon review of the cases, forty-eight were excluded: eighteen had obliterative bronchiolitis secondary to other etiologies, seventeen had an incomplete diagnosis of obliterative bronchiolitis not meeting study criteria, eight did not have obliterative bronchiolitis, three were excluded for radiologic emphysema, and two did not have rheumatoid arthritis. After exclusion of nonqualifying patients, forty-one fulfilled the criteria for diagnosis of RA-OB. In most patients, the clinical, physiologic and radiologic findings precluded the need for confirmatory histopathologic diagnosis.

Demographic characteristics are presented in Table 1. There was notable female predominance (93%F:7%M) with a mean age of 57 ± 15 years (range, 22 to 84) at the time of diagnosis. Six were smokers without radiologic evidence of emphysema. Patients had a diagnosis of RA on average fourteen years before the diagnosis of RA-OB. Four patients were diagnosed with small airways disease either concomitantly or during the same year of their RA diagnosis. One patient had an overlap syndrome with RA.
and systemic lupus erythematosus (SLE). During the study period, patients received a wide range of therapeutic agents. Ten percent were previously on D-penicillamine. Twenty-four percent had non-pulmonary extra-articular manifestations. Specifically, 17% had secondary Sjögren’s syndrome. In addition to obliterative bronchiolitis, the majority had other rheumatoid arthritis-associated pulmonary disease, most commonly pulmonary nodules and/or bronchiectasis.

Dyspnea was the primary respiratory symptom, present in nearly all patients (92.7%). Thirty-nine percent had active joint symptoms at the time of diagnosis. Eleven underwent histologic assessment, consisting of surgical or transbronchial biopsy. Fifty percent of histopathologic slides were confirmatory, the rest were non-diagnostic with the majority showing non-specific chronic inflammation. Interestingly, all five surgical biopsies resulted in confirmatory histopathologic findings. In comparison, only two of the seven transbronchial biopsies resulted in confirmatory findings. This included one patient who underwent both wedge and transbronchial biopsies. Chest CT was obtained in 95% of patients, which revealed mosaic attenuation in 51.3%. Expiratory views were performed in 72% of CT studies. Physiologic studies were obtained at diagnosis and at last available follow-up (Table 2). Eighty-five percent had evidence of obstruction at initial assessment. There appeared to be no statistically significant absolute change in TLC%, FEV1%, FVC%, and DLCO% obtained at diagnosis and last available follow-up (median duration between PFTs of 33 months (IQR 14.6–51.7)). Mean percent change per year was also calculated in those with available follow-up study for each PFT parameter. Mean FEV1% change per year was −0.4% with a mean increase in TLC% of 1.5% per year.

Thirty-two patients received directed medical therapy for RA-OB including long-acting inhalers (bronchodilators and inhaled corticosteroids), systemic corticosteroids or other immunosuppressive agents, and macrolide antibiotics (Table 3). Five patients were on supplemental oxygenation, and one underwent lung transplantation. Patients were followed for median duration of 61.7 months (IQR 32.1–113.1). All-cause mortality was 27% over the follow-up timeline. Clinical variables were assessed for their contribution to all-cause mortality (Table 4). No distinguishable predictors of survival at presentation were found on Cox regression analysis.

### Discussion

To our knowledge, this study represents the largest case series to date of patients with rheumatoid arthritis-associated obliterative bronchiolitis. The syndrome occurs primarily in middle-aged women after more than a decade of rheumatoid arthritis. The majority presented with dyspnea and radiologic findings of mosaic attenuation and centrilobular nodules. Serial pulmonary function testing demonstrated severe (median FEV1 40%) but stable obstructive disease over time. Seventy-eight percent received directed therapy including long-acting inhalers, systemic corticosteroids or other immunosuppressive agents, and macrolide antibiotics. All-cause mortality was 27% over a median follow-up of five years, without any distinguishable predictors of survival at presentation on Cox regression analysis.

Obliterative bronchiolitis has been described in the literature as a manifestation of underlying rheumatologic disease or secondary to its therapeutic agents. Geddes et al.
been observed in other studies [16, 23] and may reflect on D-penicillamine. 

findings [12, 16]. In our study, only 10% were previously 

arthritis and obliterative bronchiolitis was fourteen years. 

ship between gender and mortality. 

in connective tissue disease-associated obliterative bron-

male gender was an independent predictor of mortality 

the female predominance associated with rheumatoid 

This duration is longer than the five to ten years found 

in patients due to lack of recognition by local 

providers and thus reflect referral bias in a tertiary care 

center. It may also be confounded by earlier diagnosis of 

was delayed in patients on D-penicillamine therapy, raising the possibil-

ity of drug-induced bronchiolopathy [12, 13, 16]. However, 

patients treated with D-penicillamine for other conditions, 

such as Wilson’s disease, did not develop similar airway 

findings [12, 16]. In our study, only 10% were previously 

on D-penicillamine. 

The majority of our patients were female. This has also 

been observed in other studies [16, 23] and may reflect 

the female predominance associated with rheumatoid 

arthritis. Interestingly, Fernandez Perez et al. noted that 

male gender was an independent predictor of mortality 

in connective tissue disease-associated obliterative bron-

chiolitis [24]. Our study did not show a similar relation-

ship between gender and mortality. 

The mean interval between diagnosis of rheumatoid 

arthritis and obliterative bronchiolitis was fourteen years. 

This duration is longer than the five to ten years found 

in other studies [18, 19]. The diagnosis of RA-OB may 

be delayed in patients due to lack of recognition by local 

providers and thus reflect referral bias in a tertiary care 

center. It may also be confounded by earlier diagnosis of 

rheumatoid arthritis. Similar to other studies [16, 18, 19], 

we found that initial clinical presentation of airways 

disease was non-specific with predominant symptoms 

of dyspnea and cough. Less than 40% had active joint 
symptoms at diagnosis, similar to findings by Devouassoux 
et al. [19]. A quarter of patients had non-pulmonary and 
extra-articular manifestations, most commonly secondary 
Sjögren’s. Geli et al. reviewed the CT findings of patients 
with primary Sjögren’s and noted that 65% had bronchi-
olar abnormalities [25]. This incidence may be a reflection 
of the association between bronchiolopathies and gen-

eralized connective tissue disorders. It is unclear whether 

secondary Sjögren’s affects the development or clinical 
course of obliterative bronchiolitis in patients with RA. 

Further studies to evaluate the relationship between ob-
literative bronchiolitis and primary versus secondary 
Sjögren’s syndrome are needed. 

While our study did not evaluate chest radiographs, 
prior studies reported radiologic findings such as hyper-
inflation and hyperlucency [18, 19]. We found that half 
of our patients had characteristic findings of mosaic atten-
duation with expiratory air trapping on CT [18]. We 
suspect the frequency of mosaic attenuation may be 
under-estimated as expiratory images were not routinely 

obtained on chest CT at presentation (only 72% had spe-
cific expiratory images). We note that Devouassoux et 
al. found a high prevalence of emphysema on CT in pa-
tients with RA-OB, even in nine non-smokers [19]. We 
specifically excluded those with radiologic evidence of 
emphysema given concern for confounding of PFT se-
verity and long-term survival by this finding. This may 
have resulted in a more biased subset of individuals, not 
reflecting the possible co-existence of small airways dis-
ease and emphysema in non-smokers. In general, patients 
with rheumatoid arthritis often have several or multiple 
radiologic abnormalities on high-resolution chest CT. 
Remy-Jardin and colleagues found the most common ab-
normalities were bronchiectasis and bronchiolectasis [26], 
as airways disease is often the earliest manifestation of RA

| Table 3 Treatment and Outcome |

Directed therapy (N = 32, 78.0%) |

Long-acting inhaler, N (%) | 27 (84.4) |
Systemic corticosteroids, N (%) | 10 (31.3) |
Macrolides, N (%) | 18 (56.3) |
Oxygen supplementation at rest |
Less than or equal to 3 L O2, N (%) | 4 (12.5) |
Greater than 3 L, N (%) | 1 (3.1) |
Transplantation, N (%) | 1 (3.1) |
Mortality, N (%) | 11 (26.8) |
Time from OB diagnosis to death, months (mean ± SD) | 54 ± 53 |

Abbreviations: TLC% percent of predicted total lung capacity, RV/TLC% percent of predicted residual volume over total lung capacity, FVC% percent of predicted forced expiratory volume in the first second

¶Wilcoxon signed rank test for comparing two related samples

Table 2 Pulmonary Function Testing (PFTs)

| PFTs at diagnosis (N = 40) | Last PFTs (N = 25) | Total mean change from first to last PFT, % predicted (N = 25) | Mean % change per year | P-value
|---|---|---|---|---|
Obstruction, N (%) | 34 (85.0) | 21 (84.0) | 4.8 | 1.5 (N = 15) | 0.46
TLC% (median (IQR)) | 106 (88.0–115.0) | 112 (105.0–123.0) | –6.6 | –1.7 (N = 14) | 0.07
RV/TLC% (median (IQR)) | 158 (144.0–181.5) | 152 (146.3–166.8) | –1.9 | –0.5 (N = 25) | 0.42
FVC% (median (IQR)) | 66 (53.0–75.0) | 61 (54.5–74.5) | –1.5 | –0.4 (N = 25) | 0.43
FEV1% (median (IQR)) | 40 (31.0–52.5) | 41 (29.5–48.0) | –2.3 | –0.6 (N = 18) | 0.34
DLCO% (median (IQR)) | 69 (57.5–78.0) | 64 (57.0–76.8) | –3.2 | –1.6 (N = 25) | 0.64

Duration between first and last available PFT, months (median (IQR and mean (SD))

33(14.6–51.7), 42 (40)

Abbreviations: TLC% percent of predicted total lung capacity, RV/TLC% percent of predicted residual volume over total lung capacity, FVC% percent of predicted forced vital capacity, FEV1% percent of predicted forced expiratory volume in the first second

¶Wilcoxon signed rank test for comparing two related samples
in the lung [3]. In contrast, Tanaka et al. reported a higher prevalence of interstitial findings, such as ground glass opacities or reticulation. This discrepancy may be the result of referral bias, as many of the patients included in this study were first evaluated in an interstitial lung disease clinic [27]. In our series, the most common radiologic finding was pulmonary nodules, followed by bronchiolar abnormalities. The predominance of bronchiectasis is consistent with RA with or without obliterative bronchiolitis. In advanced cases of obliterative bronchiolitis, there may be wall thickening in both small and large airways. Interestingly, only 30% of our patients had evidence of fibrosis. This lower percentage may be a reflection of gender differences, as rheumatoid arthritis-associated pulmonary fibrosis is more common in males than females [3]. None of these additional findings on their own contributed to an increased risk of mortality, as assessed by univariate Cox regression analysis, likely due to the limited sample size and number of events (deaths) in our series.

Diagnosis of obliterative bronchiolitis may be confirmed with biopsy, either surgical or transbronchial. In our study, all surgical biopsies resulted in confirmatory histopathologic findings, compared to only two of seven transbronchial biopsies. This included one patient with both wedge and transbronchial biopsies. In our small sample size, the diagnostic yield of surgical biopsy was superior to transbronchial biopsy. Further studies to better understand the diagnostic yield of each modality are needed. While the diagnosis of RA-OB may be obtained clinically, in patients with suspected but indeterminate findings requiring histopathologic confirmation, we recommend surgical biopsy for greater yield, if feasible and safe.

In our study, pulmonary function tests were typically consistent with an obstructive pattern. There was a minority of patients with non-specific, restrictive, or normal findings. Diffusing capacity was relatively maintained in comparison to other airway or parenchymal diseases such as chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) associated with RA. While other studies have noted that FEV1 was significantly lower in patients previously on D-penicillamine [19], we did not find evidence of worsening pulmonary impairment in patients on this agent. Fernandez Perez et al. investigated the longitudinal progression of pulmonary function testing in patients with connective tissue disease associated-obliterative bronchiolitis [24]. While their study did not distinguish between underlying rheumatoid arthritis versus other connective tissue diseases, they discovered that the rate of FEV1 change was minimal during their three-year follow-up, regardless of therapy [24]. Similarly, our study cohort had minimal change in FEV1, suggesting the clinical and functional course of RA-OB may stabilize for a period of time in some.

Given the paucity of literature regarding this syndrome, current evidence for therapy is limited. Case reports mention corticosteroids [16] and other immunosuppressive agents including azathioprine [14], cyclophosphamide [23], and etanercept [28] as possible therapeutic agents directed at small airways disease. Case series have demonstrated that macrolides improve or slow the progression of respiratory impairment in RA-OB [18], which is also evident for other bronchiolar diseases [29]. Unfortunately, large randomized trials for RA-OB are lacking due to disease rarity. Our observational data reveal that medical therapy often included a combination of long-acting inhalers, systemic corticosteroids or other immunosuppressive agents, and macrolide antibiotics. Despite these options, treatment of obliterative bronchiolitis does not appear to reverse disease. It is unclear if FEV1 stabilization in our cohort was a result of natural clinical course or directed therapy. We found that all-cause mortality was 27% over a median follow-up of five years. While the severity of disease based on clinical symptoms and functional findings on PFTs was poor, there again appeared to be a fairly stable clinical course in the majority with gradual deterioration on a time scale of years. This is in contrast to other studies that highlight obliterative bronchiolitis as severe or advancing with immediate decline over months [11–14]. It remains unclear why there is such heterogeneity in disease course.

Our study has several limitations. This is a single center study assessing patients diagnosed and managed over a number of years, reflecting local practices and

| Characteristics | HR (95% CI)   | P-value |
|-----------------|--------------|---------|
| Age at diagnosis, years | 0.99 (0.94–1.03) | 0.78   |
| Gender, female | 0.93 (0.15–17.6) | 0.94   |
| Duration of RA prior to diagnosis, years | 0.98 (0.94–1.03) | 0.58   |
| Active joint symptoms at diagnosis | 1.87 (0.24–11.42) | 0.51   |
| Mosaic attenuation at diagnosis | 0.59 (0.12–2.17) | 0.44   |
| Lung fibrosis at diagnosis | 2.12 (0.58–7.76) | 0.24   |
| Bronchiectasis at diagnosis | 1.02 (0.28–3.69) | 0.97   |
| Baseline PFTs at diagnosis |            |         |
| TLC%            | 0.99 (0.95–1.04) | 0.76   |
| RV/TLC%         | 1.01 (0.98–1.03) | 0.51   |
| FVC%            | 0.94 (0.87–1.03) | 0.19   |
| FEV1%           | 0.99 (0.91–1.07) | 0.96   |
| Positive bronchodilator response | 3.41 (0.73–17.7) | 0.11   |
| Macrolide therapy | 1.73 (0.40–7.44) | 0.44   |

Abbreviations: TLC% percent of predicted total lung capacity, RV/TLC% percent of predicted residual volume over total lung capacity, FVC% percent of predicted forced vital capacity, FEV1% percent of predicted forced expiratory volume in the first second, RA rheumatoid arthritis.
their evolution over time. Patients referred to tertiary care centers may have more advanced or refractory disease, and thus may not be fully representative of the general disease population. Patients also had physiologic studies measured at varied intervals over time which make accurate assessment of rates of decline less reliable over the study interval. Because of the lack of standardized therapy, we were unable to make inferences about the efficacy of any particular treatment regimen on pulmonary function testing or clinical course. Lastly, as a retrospective study, exact circumstances involved in decision making are difficult to determine, particularly causal effects of management. Despite being one of the larger retrospective studies to date, the absolute number of patients still limited statistical analyses, including multivariable comparisons.

Conclusions
Rheumatoid arthritis-associated obliterative bronchiolitis appears to have a fairly stable clinical course despite persistent symptoms and severe airflow obstruction. While diagnosis may be obtained clinically using supporting radiographic evidence, in patients with suspected disease requiring histopathologic confirmation, we recommend performing surgical biopsy for greater yield, if feasible and safe. Interestingly, serial pulmonary function testing showed only mild deterioration in FEV1 over time. There were no distinguishable predictors at presentation to frame the likelihood of therapeutic response or more rapid clinical decline. Characterizing this longitudinal progression though has valuable implication in the appropriate counseling of patients and future design of clinical trials.

Abbreviations
COPD: Chronic obstructive pulmonary disease; CT: Computed tomography; DLCO: Diffusing capacity for carbon monoxide; FEV1: Forced expiratory volume in the first second; FVC: Forced vital capacity; ILD: Interstitial lung disease; IQR: Interquartile range; LLN: Lower limits of normal; OB: Obiterative bronchiolitis; PFT: Pulmonary function testing; RA: Rheumatoid arthritis; RA-OB: Rheumatoid arthritis-associated obiterative bronchiolitis; RV/TLC: Residual volume over total lung capacity; SLE: Systemic lupus erythematosus; TBB: Transbronchial biopsy; TLC: Total lung capacity.

Funding
This research received no grant from any funding agency in the public, commercial or non-profit sectors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
EL contributed to the literature search, data collection, data analysis, and data interpretation. AL contributed substantially to the literature search and study design. TM also contributed substantially to the literature search, study design, data analysis, and data interpretation. All authors participated in writing and revising the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Mayo Clinic Institutional Review Board approval was obtained (IRB #16–009418). Consent to participate was not required, given the retrospective nature of this study.

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 August 2017 Accepted: 13 June 2018
Published online: 22 June 2018

References
1. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4(5):443–8.
2. Anaya JM, Dietelheim L, Ortiz LA, Gutierrez M, Citera G, Welsh RA, Espinosa LR. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24(4):242–54.
3. Lynch DA. Lung disease related to collagen vascular disease. J Thorac Imaging. 2009;24(4):299–309.
4. Metafrazi ZM, Georgiadis AN, Ioannidou CV, Alamanos Y, Vassiliou MP, Zikou AK, Raptis G, Drosos AA, Efremidis SC. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007;36(5):338–44.
5. Silvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol. 2004;33(4):221–7.
6. Suzuki A, Ohsonoe Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, Fukuda J. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21(1):33–6.
7. Lynch JP 3rd, Weigt SS, DerHovanessian A, Fishbein MC, Gutierrez A, Belperio JA. Obliterative (constrictive) bronchiolitis. Seminars in respiratory and critical care medicine. 2012;33(5):509–32.
8. Barker AF, Bergeron A, Rom WN, Hertz ML. Obiterative bronchiolitis. N Engl J Med. 2014;370(19):1820–8.
9. Schlesinger C, Veenaghavan S, Koss MN. Constrictive (obliterative) bronchiolitis. Curr Opin Pulm Med. 1998;4(5):288–93.
10. Parambil JG, Yi ES, Ryu JH. Obstructive bronchial disease identified by CT in the non-transplant population: analysis of 29 consecutive cases. Respirology (Carlton, Vic). 2009;14(3):443–8.
11. Geddes DM, Corrin B, Brewerton DA, Davies RI, Turner-Warwick M. Progressive airway obliteration in adults and its association with rheumatoid disease. Q J Med. 1977;46(189):427–44.
12. Epler GR, Snider GL, Gaensler EA, Cathcart ES, Fitzgerald MX, Carrington CB. Bronchiolitis and bronchi in connective tissue disease. A possible relationship to the use of penicillamine. JAMA. 1979;242(6):528–32.
13. Murphy KC, Atkins CJ, Offer RC, Hogg JC, Stein HB. Obiterative bronchiolitis in two rheumatoid arthritis patients treated with penicillamine. Arthritis Rheum. 1981;24(3):557–60.
14. Penny WJ, Knight RK, Rees AM, Thomas AL, Smeth AP. Obiterative bronchiolitis in rheumatoid arthritis. Ann Rheum Dis. 1982;41(4):469–72.
15. Lahdensuo A, Mattila J, Vilppula A. Bronchiolitis in rheumatoid arthritis. Chest. 1984;85(5):705–8.
16. Yam LY, Wong R. Bronchiolitis obiterans and rheumatoid arthritis. Report of a case in a Chinese patient on d-penicillamine and review of the literature. Ann Acad Med Singap. 1993;22(3):305–8.
17. Schwartz MI, Lynch DA, Tuder R. Bronchiolitis obiterans: the lone manifestation of rheumatoid arthritis? Eur Respir J. 1994;7(4):817–20.
18. Hayakawa H, Sato A, Irimajiri K, Chida K, Kato M. Bronchiolitis disease in rheumatoid arthritis. Am J Respir Crit Care Med. 1996;154(5):1531–6.
19. Devouassoux C, Cotton V, Litoe H, Marchand F, Franchon L, Schuller A, Beju-Thivolet F, Cordier JF. Characterisation of severe obiterative bronchiolitis in rheumatoid arthritis. Eur Respir J. 2009;33(5):1051–61.
20. Annett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthria HS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.

22. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–82.

23. van de Laar MA, Westermann CJ, Wagenaar SS, Dinant HJ. Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans. Arthritis Rheum. 1985;28(1):93–7.

24. Fernandez Perez ER, Krishnamoorthy M, Brown KK, Huie TJ, Fischer A, Solomon JJ, Meehan RT, Olson AL, Swigris JJ. FEV1 over time in patients with connective tissue disease-related bronchiolitis. Respir Med. 2013;107(6):883–9.

25. Franquet T, Gimenez A, Monill JM, Diaz C, Gell C. Primary Sjogren's syndrome and associated lung disease: CT findings in 50 patients. AJR Am J Roentgenol. 1997;169(3):655–8.

26. Remy-Jardin M, Remy J, Cortet B, Mauri F, Delcambre B. Lung changes in rheumatoid arthritis. CT findings. Radiology. 1994;193(2):375–82.

27. Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, Emoto T, Matsumoto T, Lynch DA. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232(1):81–91.

28. Cortot AB, Cortin V, Miossec P, Fauchon E, Thivolet-Bejui F, Cordier JF. Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. Respir Med. 2005;99(4):511–4.

29. Yadav H, Peters SG, Keogh KA, Hopan WJ, Enwin PJ, West CP, Kennedy CC. Azithromycin for the treatment of Obliterative bronchiolitis after hematopoietic stem cell transplantation: a systematic review and meta-analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016;22(12):2264–9.